Veracyte, Inc. (VCYT) P/E Ratio History
Historical price-to-earnings valuation from 2024 to 2025
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 5, 2026, Veracyte, Inc. (VCYT) trades at a price-to-earnings ratio of 44.2x, with a stock price of $36.27 and trailing twelve-month earnings per share of $0.82.
The current P/E is 49% below its 5-year average of 86.2x. Over the past five years, VCYT's P/E has ranged from a low of 51.6x to a high of 132.0x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.2x, VCYT trades at a 91% premium to its sector peers. The sector includes 226 companies with P/E ratios ranging from 0.0x to 194.6x.
Relative to the broader market, VCYT commands a significant premium over the S&P 500 median P/E of 26.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our VCYT DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Diagnostics and Omics Tools peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| VCYTVeracyte, Inc. | $3B | 44.2Lowest | -Best | +165%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $42.10 | $0.82 | 51.6x | -40% |
| FY2025 Q3 | $34.33 | $0.38 | 91.4x | +6% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $27.03 | $0.33 | 83.0x | -4% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $29.65 | $0.41 | 72.7x | -16% |
| FY2024 Q4 | $39.60 | $0.30 | 132.0x | +53% |
Average P/E for displayed period: 86.2x
See VCYT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VCYT Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare VCYT vs LLY
See how VCYT stacks up against sector leader Eli Lilly and Company.
Start ComparisonFrequently Asked Questions
Is VCYT stock overvalued or undervalued?
VCYT trades at 44.2x P/E, below its 5-year average of 86.2x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does VCYT's valuation compare to peers?
Veracyte, Inc. P/E of 44.2x compares to sector median of 23.2x. The premium reflects expected growth above peers.
What is VCYT's PEG ratio?
VCYT PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2024-2025.